Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer

Inclusion Criteria: * The subject has given written, informed consent and is available for the duration of study * Histologically or cytologically confirmed diagnosis of breast cancer * Male or female aged ≥ 18 years * Females subjects of child-bearing potential must have a negative urine pregnancy test * Female subjects must be non-lactating and non-breastfeeding * Subject must be willing and able to comply with scheduled visits, treatment plan and laboratory testing Exclusion Criteria: * Known hypersensitivity to either of the study drugs or their excipients * Inability to undergo venipuncture and/or tolerate venous access * Pre-existing clinically significant peripheral neuropathy * Positive laboratory exclusion test (HIV, HBsAg, or HCV) * Treatment with investigational agents or participation in clinical trial within 30 days of study entry